The plasticity of a cell is one of its quietly profound advantages picture cells glowing from an extraneous DNA vector incorporated into the genome or cells that acquire newfound targeting abilities to find and kill problematic tumors.
Superpowered cells cloaked with superhuman abilities are what unify the burst of engineered cell therapies that are exploding on the biopharmaceutical scene. This includes chimeric antigen receptor(CAR)-T cell therapies, where different cell types are armored with receptors that can latch onto and kill cancer cells. Or,reprogrammed stem cellsthat replace certain cell types lost during diseases like diabetes, as well asCRISPR-Cas9 editingof existing cells to correct blindness.
These exciting therapeutic possibilities have created a whole host of new questions: how, for instance, can we mass manufacture enough personalized cells to satisfy millions of patients? How can we ensure therapeutic quality? How can we truly understand that the changes made to these cells are helpful to the patient rather than harmful?
Several biotechnology companies are pushing to answer some of those questions.Cellaresis focused on creating a solution to the issue of mass manufacturing.Mission Bioisdeveloping sequencing platforms that can better understand the genetic changes in cell therapies and various patients. Both companies are part of the rapidly evolving push to create and characterize the superhuman powers cells can be endowed with.
Cellares aims to develop scalability hoping for a cell therapy future without engineering bottlenecks. Earlier this year, the company raised$82 million in Series B fundingto continue the development of their Cell Shuttle, a cell therapy factory-in-a-box that aims to fully automate cell therapy workflows.
2017 marked the beginning of the commercialization phase in cell therapies when the first CAR-T cell therapies were FDA-approved. Prior to that, nobody was faced with the challenge of how you could scale this out to tens and hundreds of thousands of patients per year, per drug, said Fabian Gerlinghaus, CEO at Cellares. The problem is new, and the problem is unsolved.
Cellares technology revolves around their GMP (good manufacturing practice)-in-a-box cartridge. The cartridge is a single use consumable that reduces the need for human action to merely load and unload the cells. On a larger scale, the Cell Shuttle system is the combination of cartridges and various bioprocessing instruments contained inside a robotic work cell that maintains an enclosed GMP environment. The process becomes user-controlled and customized through a centralized software solution.
According to Gerlinghaus, the very capability to load 10 cartridges at once allows for a dramatic escalation in manufacturing capacity. Additionally, the components that make up the Cell Shuttle allow for a high degree of customer and, subsequently patient, personalization. You can run 10 different processes with different process parameters and workflows simultaneously on the same platform, he explained. High level customization happens by choosing which of our modular instruments were actually going to be putting on the Cell Shuttle to support your workflow. Low-level customization to a particular process happens in user-facing software, which leverages the flexibility of our modular system architecture.
Capability-wise, Gerlinghaus stated that the Cell Shuttle supports all of the typical cellular manufacturing unit operations, which include cell enrichment, selection systems, cell activation, non-viral/viral gene transfer, cell washing, media or buffer changes, and automated sampling.
The entire design intent with our software platform is to put the power into the hands of process development scientists or pharma companies to create and run the processes that define their products, he added.
While Cellares tackles the problem of mass-manufacturing cell therapies, the question of understanding genomic changes both in the cell therapy and in the patient themselves persists. This is where Mission Bio carves a niche for itself. The biotechnology company uses single-cell DNA sequencing and multi-nomics approaches to understand, on a per-cell basis, how certain perturbations change the genome.
Mission Bios Tapestri platform utilizes a microfluidics-based approach to simultaneously sequence targeted DNA and identify cell-surface proteins in individual cells. First, a single-cell suspension is generated by the scientist. This suspension is incubated with oligo-conjugated antibodies, which recognize and tag specific proteins. The solution is loaded onto the Tapestri platform, where each cell is encapsulated into a droplet. Within each droplet, a protease reaction first digests the chromatin surrounding DNA.
Next, each droplet flows into a second, separate droplet, where targeted DNA and protein tags are amplified through a polymerase chain reaction, allowing for subsequent amplification and sequencing. Ultimately, the read-out includes the genotype and immunophenotype to portray a more holistic picture of the cells genome.
Why, then, choose to leverage sequencing technology on a single cell level as opposed to a bulk level? When we do bulk [sequencing], we assume that the sample is homogeneous, said Dr. Yan Zhang, PhD, CEO at Mission Bio. But that is not true. We know that biological samples are heterogeneous. If you just use bulk sequencing, you cannot get a high level of specificity.
While sequencing technologies (some offering single cell resolution) have become highly popularized in recent years, Mission Bios Tapestri is crucially different from the popular RNA-sequencing platforms dominating the field today. Rather than looking at gene expression, as is the goal of RNA-sequencing, Tapestri looks at the genome itself. This is particularly useful for diseases like cancer, where patients can have drastically variable DNA mutations in certain cells that would render one drug more effective than another. This is also useful for cell engineering, where traditional quality-control methods rely on growing out single cell clones for selection and downstream genome analysis a time-consuming task.
Zhang raised the example of scientists aiming to CRISPR-edit cells, where a potential goal is to make 27 separate edits in a single cell. Without single cell sequencing resolution, it is difficult to identify which cells have been reprogrammed with all 27 edits, as opposed to 3 or even 26 of those edits. With our technology, they could distinguish [the cells with all 27 edits], Zhang said. They were able to optimize the conditions improving the desired edit efficiency from 2% to 50%.
In the future, Zhang hopes that Tapestri will be leveraged as a strategy to monitor the cells of patients undergoing cell or gene therapy. The desire for cell and gene therapy is to cure patients with a single dose that can last for a lifetime, she explained. But its still very early, and we still need to understand and monitor the patients. Our technology, at least how we see it, is extremely powerful for accelerating development, giving you much better insight into safety, efficacy, toxicity, and metabolism.
Mission Bio has recently releasedTapestri Cell & Gene Therapy Solutions, aimed towards quickly characterizing genetically edited, superpowered cells in cell and gene therapy development pipelines. Meanwhile, Cellares continues to develop its Cell Shuttle, with an anticipated market release in late 2023. Both companies are actively pursuing partnerships to both broaden and develop their technologies. Tapestri has been cited in papers tracingCRISPR-edited cellsandleukemia, while Cellares announced a partnership withPoseida Therapeuticsas part of their Early Access Program.
Altogether, the journey to create and understand a superpowered cell continues. For Gerlinghaus, a former aerospace engineer, this commitment to ensuring quality and scale, combined with special powers, persists. Were taking a very systematic approach, which ultimately will result in a very reliable solution for pharma companies that ultimately benefits patients, he said. The level of reliability that were going for with our equipment is akin to the level of reliability of an airplane."
Read the rest here:
Biotech Companies are Expanding the Frontiers of Engineered Cell Therapy - BioSpace
- John Cleese says he's been spending 17,000 annually on stem cell therapy to 'buy a few extra years' - Yahoo News UK - April 24th, 2024
- Promethera Bets Liver-Derived Stem Cells Will Offer Benefits In NASH - Scrip - April 24th, 2024
- Stem Cell Therapies: Is This The Future Of Wellness? - Grazia USA - April 20th, 2024
- Signal of Benefit for Stem Cell Therapy in Progressive MS - Medscape - March 7th, 2024
- The Controversies Surrounding Stem Cell Therapy for Autism - The Portugal News - February 24th, 2024
- Benefits of Stem Cell Therapy - News Channel 5 Nashville - February 7th, 2024
- What is Stem Cell Therapy & How It Helps Others - Publicist Paper - January 31st, 2024
- A guide to stem cell therapy in Thailand - Thaiger - January 4th, 2024
- Half of pediatric patients with aHUS benefit from Soliris after... - AHUS News - December 21st, 2023
- Real world analysis on the determinants of survival in primary ... - Nature.com - December 5th, 2023
- The Best Beauty Gifts According To People Who Really Know Skin Care - HuffPost - December 5th, 2023
- The Eyepopping Factory Construction Boom in the US - WOLF STREET - December 3rd, 2023
- Benefit of Neoadjuvant Therapy Illustrated During ESMO Congress ... - Targeted Oncology - December 1st, 2023
- Benefits Outweigh Risks as FDA Inspects CAR-T Cell Therapy ... - Curetoday.com - December 1st, 2023
- Review What Real Cavityn Customers Say About Benefits and Side ... - Seattle Weekly - December 1st, 2023
- 'There is a Scientific Fraud Epidemic' - Slashdot - Slashdot - December 1st, 2023
- 15 Best Hydrating Serums to Soothe Any Skin Type 2023 - Town & Country - December 1st, 2023
- Innovations in Cosmetic Dermatology: A Glimpse into the Future - APN News - December 1st, 2023
- FDA Probes New Cases of Cancer That May Stem From Cancer Cell ... - MedCity News - November 29th, 2023
- Use of plant stem cells in topical formulations on the rise - CosmeticsDesign.com USA - November 29th, 2023
- Stem cell-based treatment controls blood sugar in people with Type ... - EurekAlert - November 29th, 2023
- Biologics Market is projected to grow at a CAGR of 8.5% by 2034: Visiongain - Yahoo Finance - November 29th, 2023
- Scientists devise new technique that can pinpoint the causes and ... - EurekAlert - November 29th, 2023
- Global Advanced Therapy Medicinal Products Market is on the brink ... - PharmiWeb.com - November 29th, 2023
- Introducing Orgavalue - The 2023 EIT InnoStars Awards winner - EU-Startups - November 29th, 2023
- Episode 160: Euan Ashley discusses precision medicine and the ... - IHMC - November 29th, 2023
- Is Phenq Right For You? Review The Facts Before Making a ... - Vashon-Maury Island Beachcomber - November 27th, 2023
- Cavityn Reviews - Does It Work? Cheap Scam or Effective ... - The Daily World - November 25th, 2023
- Trend Hunting With Beautystreams At Cosmoprof Asia 2023 - BeautyMatter - November 25th, 2023
- FDA Considers First CRISPR Gene Editing Treatment That May ... - Slashdot - November 25th, 2023
- How Do Plants Determine Where the Light Is Coming From? - Lab Manager Magazine - November 25th, 2023
- Deaths From Coal Pollution Have Dropped, But Emissions May be ... - Slashdot - November 25th, 2023
- Stem cell-based therapies for stroke in newborns - Cochrane - November 23rd, 2023
- Dr Leslie on Outpatient CAR T-Cell Therapy Programs for ... - OncLive - November 23rd, 2023
- Human Milk-Based Therapy May Be Beneficial in Blood Cancers - Curetoday.com - November 23rd, 2023
- Oncological Horizons: The Synergy of Medical and Surgical ... - Cureus - November 23rd, 2023
- Human and environmental safety of carbon nanotubes across their ... - Nature.com - November 23rd, 2023
- Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted ... - BioSpace - November 23rd, 2023
- #HearTheMarsdenKids call on NHS London to reconsider cancer ... - Metro.co.uk - November 23rd, 2023
- Diagnosis and Management of Cardiovascular Risk in Patients with ... - Dove Medical Press - November 23rd, 2023
- BioLineRx Reports Third Quarter 2023 Financial Results and ... - PR Newswire - November 21st, 2023
- Why our Award Winners Beauty Box is the ultimate beauty gift (for ... - Yahoo Singapore News - November 21st, 2023
- SightCare Reviews - Is Official Website for Sight Care Legit to Try or ... - Vashon-Maury Island Beachcomber - November 21st, 2023
- Legend Biotech Reports Third Quarter 2023 Results and Recent ... - StreetInsider.com - November 21st, 2023
- Lorenzo's Oil: Can It Really Treat ALD? - Verywell Health - November 19th, 2023
- Doctor Says Living To 120 By End Of Decade Is Possible What's the Secret? - Benzinga - November 19th, 2023
- The week in pharma: action, reaction and insight week to ... - The Pharma Letter - November 19th, 2023
- Race Cannot Be Used To Predict Heart Disease, Scientists Say ... - Slashdot - November 19th, 2023
- SpaceX's Starship Reaches Outer Space Before Intentional ... - Slashdot - November 19th, 2023
- Mesenchymal Stem Cells Market is projected to reach USD 3,319 million by 2030 according to a new research r... - WhaTech Technology and Markets News - November 17th, 2023
- LMRUK: Protecting the next generation through cord blood - Charity Today News - November 17th, 2023
- Anti-aging molecule discovered that extends lifespan - Earth.com - November 17th, 2023
- Montana State researcher envisions living building materials that ... - Montana State University - November 17th, 2023
- OxyHelp Explores the Benefits of Hyperbaric Oxygen Therapy for ... - StreetInsider.com - November 15th, 2023
- Health benefits of bone marrow - Pakistan Observer - November 15th, 2023
- Evolving the standard of care: What is next for functional ... - NeuroNews International - November 15th, 2023
- Affimed Reports Third Quarter 2023 Financial Results and ... - BioSpace - November 15th, 2023
- Meet the World's First Whole-Eye Transplant Recipient - TIME - November 15th, 2023
- Calidi Biotherapeutics Reports Third Quarter 2023 Operating and ... - Business Wire - November 15th, 2023
- 10 Asia-Pacific biotech companies leading innovation in the region - Labiotech.eu - November 15th, 2023
- Fitspresso Reviews (November Update) Natural Ingredients That ... - Bainbridge Island Review - November 15th, 2023
- 2seventy bio Reports Third Quarter Financial Results and Recent ... - Business Wire - November 15th, 2023
- Japan To Create $6.6 Billion Fund To Develop Outer Space Industry ... - Slashdot - November 15th, 2023
- Be The Match, Healthcare Marketing Impact Awards 2023 - Ad Age - November 13th, 2023
- Medicare coverage saves lives. Enrolling shouldn't be this ... - Kevin MD - November 13th, 2023
- Future Ocean Foods: 36 Global Alt-Seafood Startups Form Association To Tackle Overfishing, Microplastics & More - Green Queen Media - November 13th, 2023
- Orchard Therapeutics Reports Third Quarter 2023 Financial Results ... - StreetInsider.com - November 13th, 2023
- Celebrity doctor reveals Hollywoods hidden trend of stem cell antiaging therapies - Longevity.Technology - November 11th, 2023
- Amazon Expands Healthcare Push With One Medical Benefits For ... - Slashdot - November 11th, 2023
- Bene Meat Technologies becomes the first to receive EU approval ... - Pet Food Processing - November 11th, 2023
- FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma - Yahoo Finance - November 11th, 2023
- MaaT Pharma Provides Third Quarter 2023 Business Update and ... - Business Wire - November 11th, 2023
- IN8bio Reports Third Quarter 2023 Financial Results and Provides ... - GlobeNewswire - November 11th, 2023
- Fast Lean Pro Reviews - Overpriced or Optimal Ingredients That ... - Journal of the San Juan Islands - November 11th, 2023
- Fate Therapeutics Reports Third Quarter 2023 Financial Results and ... - GlobeNewswire - November 11th, 2023
- Worlds first whole-eye and partial face transplant gives Arkansas man new hope - CNN - November 9th, 2023
- Glowing Fingertips And Green Eyes: First-of-Its-Kind Monkey ... - ScienceAlert - November 9th, 2023
- 10 Natural Body Scrubs That Exfoliate And Invigorate My Skin - PINKVILLA - November 9th, 2023
- CRISPR Therapeutics Provides Business Update and Reports Third ... - StreetInsider.com - November 9th, 2023
- Fate Therapeutics Reports Third Quarter 2023 Financial Results and ... - StreetInsider.com - November 9th, 2023
Recent Comments